Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.
Journal Information
Full Title: Eur Arch Psychiatry Clin Neurosci
Abbreviation: Eur Arch Psychiatry Clin Neurosci
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Conflict of interestHR and MD are employees of Boehringer Ingelheim Pharma GmbH & Co. KG and GW is an employee of Boehringer Ingelheim Pharmaceuticals Inc. Ethics approvalThe manuscript does not contain clinical studies or patient data. Consent to participateThe manuscript does not contain clinical studies or patient data. Conflict of interest HR and MD are employees of Boehringer Ingelheim Pharma GmbH & Co. KG and GW is an employee of Boehringer Ingelheim Pharmaceuticals Inc."
"Funding The review article was funded by Boehringer Ingelheim."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025